Abstracts tagged "antiphospholipid syndrome"

Abstract Number: 172 • 2018 ACR/ARHP Annual Meeting
Serum Chemokines and miRNA Levels and Its Association with Cumulative Organ Damage in Patients with Antiphospholipid Syndrome: A Bench to Bedside Study
Laura-Aline Martinez-Martinez¹, Fausto Sanchez-Muñoz², Maya Jazmin Nastia Nicte Chacon-Perez², Yaneli Juarez-Vicuña², Nicole Mouneu Ornelas¹, Anthony Beltran-Cortez², Ricardo Alberto Venegas Yañez³, Julio Fonseca Basurto¹, Evelyn Aranda Cano¹, Mary Carmen Amigo⁴ and Luis M. Amezcua-Guerra¹, ¹Rheumatology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, ²Immunology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, ³Reumatologia, Instituto Nacional de Cardiología "Ignacio Chavez", Ciudad de México, Mexico, ⁴Rheumatology, Centro Medico ABC, Mexico, Mexico
Background/Purpose: Recent evidence suggests that chemokines and miRNAs are involved in the pathogenesis of antiphospholipid syndrome (APS). However, the specific role of these molecules in…
Abstract Number: 174 • 2018 ACR/ARHP Annual Meeting
Rivaroxaban Versus Warfarin As Secondary Thromboprophylaxis in Patients with Antiphospholipid Syndrome: A Randomized, Multicenter, Open-Label, Clinical Trial
Josefina Cortés-Hernández¹, Luis Sáez-Comet², Antoni Riera Mestre³, A. Castro Salomó⁴, J. Cuquet Pedragosa⁵, Vera Ortiz-Santamaría⁶, M. Mauri Plana⁷ and Josep Ordi-Ros⁸, ¹Internal Medicine Department, Vall d´Hebron Hospital, Barcelona, Spain, ²Internal Medicine, Miguel Servet University Hospital, Zaragoza, Spain, ³VTE Unit. Internal Medicine, Bellvitge University Hospital, Barcelona, Spain, ⁴Hospital Universitari de Reus, Spain, Reus, Spain, ⁵Internal Medicine, Granollers University Hospital, Granollers, Spain, ⁶Rheumatology, Hospital General. Granollers., Granollers, Spain, ⁷Internal Medicine, Mataró Hospital, Mataró, Spain, ⁸Internal Medicine, Vall d'Hebron Hospital, Barcelona, Spain
Background/Purpose: Long-term anticoagulation with vitamin K antagonists (VKAs) is the standard of care in thrombotic antiphospholipid syndrome (APS) but requires frequent monitoring and dose adjustment.…
Abstract Number: 851 • 2018 ACR/ARHP Annual Meeting
Integrin Mac-1 Potentiates Neutrophil Adhesion and NET Release in Antiphospholipid Syndrome
Gautam Sule¹, William J. Kelley¹, Srilakshmi Yalavarthi¹, Alison Banka¹, Andrew Vreede², Omolola Eniola-Adefeso¹ and Jason S. Knight³, ¹University of Michigan, Ann Arbor, MI, ²Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, ³., University of Michigan, Ann Arbor, MI
Background/Purpose: While the role of antiphospholipid antibodies in activating endothelial cells has been extensively studied, the impact of these antibodies on the adhesive potential of…
Abstract Number: 856 • 2018 ACR/ARHP Annual Meeting
Integrated mRNA and microRNA Transcriptomes of Monocytes from Antiphospholipid Syndrome Patients Identifies Molecular Networks Related to Their Atherothrombotic Status. Modulatory Effects of In Vivo Ubiquinol Supplementation
Carlos Perez-Sanchez¹, Laura Pérez Sánchez², Alejandra Maria Patiño-Trives³, María Luque Tevar³, Luca Scudeler⁴, Alejandro Ibáñez-Costa³, Patricia Ruiz-Limon⁵, Yolanda Jiménez-Gómez¹, Ivan Arias de la Rosa⁶, Maria Carmen Abalos-Aguilera⁶, Pedro Segui⁷, Nuria Barbarroja¹, Jose Manuel Villalba⁸, Eduardo Collantes Estevez³, Maria Jose Cuadrado⁹, Maria Ángeles Aguirre Zamorano¹ and Chary Lopez-Pedrera³, ¹Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ³IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ⁴Università degli Studi di Torino, Turin, Italy, ⁵Research Group of Endocrine Diseases, Research Laboratory. Biomedical Research Institute of Malaga (IBIMA).Virgen de la Victoria Universitary Hospital, Malaga, Spain., Málaga, MA, Spain, ⁶Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ⁷Radiology, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ⁸Departamento de Biologia Celular, Fisiologia e Inmunología, University of Córdoba, Cordoba, Spain, ⁹Clinica Universidad de Navarra, Madrid, Spain
Background/Purpose: 1. To characterize the mRNAs and microRNAs transcriptomes of monocytes, key immune cells in the atherothrombotic pathology of Antiphospholipid Syndrome patients (APS). 2. To…
Abstract Number: 1085 • 2018 ACR/ARHP Annual Meeting
Natural Gingerols Inhibit Neutrophil Extracellular Trap Release Elicited By Lupus Autoantibodies
Ramadan A. Ali¹ and Jason S. Knight², ¹University of Michigan, Ann Arbor, MI, ²., University of Michigan, Ann Arbor, MI
Background/Purpose: Recent studies have revealed a role for neutrophils in the pathogenesis of lupus and antiphospholipid syndrome (APS). Indeed, neutrophils are activated by various disease-relevant…
Abstract Number: 1100 • 2018 ACR/ARHP Annual Meeting
The Frequencies and Molecular Profiles of CD16+ Monocyte Subsets in Patients with Systemic Lupus Erythematosus, Primary Antiphospholipid Syndrome, and Antiphospholipid Syndrome with Lupus, Identify Specific Clinical Features of These Diseases
Chary Lopez-Pedrera¹, Maria Ángeles Aguirre Zamorano¹, Nuria Barbarroja², Patricia Ruiz-Limon³, Maria Carmen Abalos-Aguilera⁴, Yolanda Jiménez-Gómez², Ivan Arias de la Rosa⁴, Pedro Segui⁵, Rafaela Ortega-Castro², Eduardo Collantes Estevez¹, Alejandro Escudero-Contreras⁴, Lucas Le Lann⁶, Christophe Jamin⁶, Concepcion Marañón⁷, Marta Alarcón-Riquelme⁸, Jacques-Olivier Pers⁶ and Carlos Perez-Sanchez², ¹IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ³Research Group of Endocrine Diseases, Research Laboratory. Biomedical Research Institute of Malaga (IBIMA).Virgen de la Victoria Universitary Hospital, Malaga, Spain., Málaga, MA, Spain, ⁴Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ⁵Radiology, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ⁶U1227, Université de Brest, Inserm, Labex IGO, CHU de Brest, Brest, France, ⁷GENYO, Centre for Genomics and Oncological Research Pfizer, University of Granada, Andalusian Regional Government, Granada, Spain, ⁸Medical Genomics, Center for Genomics and Oncological Research (GENYO), Granada, Spain
Background/Purpose: This study, developed within the IMI-JU project PRECISESADS framework, aimed to determine the enrichment on CD14+ and CD16+ monocyte subpopulations in SLE, APS and…
Abstract Number: 2137 • 2018 ACR/ARHP Annual Meeting
Primary Antiphospholipid Syndrome with Vascular Manifestations Is a Rare Disease: A Population-Based, Multi-Source Study Assessing the Prevalence and Incidence in Adults
Cecilia Nalli¹, Greta Pascariello¹, Arianna Zentilin¹, Elena Raffetti², Laura Andreoli¹, Rajesh Kumar¹, Giuliana Martini³, Roberta Ottaviani¹, Cinzia Gasparotti⁴, Michele Magoni⁴, Carmelo Scarcella⁴, Francesco Donato⁵ and Angela Tincani¹, ¹Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ²Epidemiology and Public Health Intervention Research group (EPHIR), Department of Public Health Sciences, Karolinska Institutet, Solna, Sweden, ³Hemostasis and Thrombosis Center, Spedali Civili of Brescia, Brescia, Italy, ⁴ATS Brescia (Brescia Health Protection Agency), Brescia, Italy, ⁵Department of Medical and Surgical Specialties Radiological Sciences and Public Health, Unit of Hygiene, Epidemiology, and Public Health, University of Brescia, Italy., Brescia, Italy
Background/Purpose: Antiphospholipid Syndrome (APS) is a systemic autoimmune disease characterized by thrombotic and/or obstetrical manifestations mediated by antiphospholipid antibodies (aPL). By now, no population-based study…
Abstract Number: 156 • 2018 ACR/ARHP Annual Meeting
Assessing the Role of Ascvd Score in Primary Thrombosis Prophylaxis Strategy Among Asymptomatic Antiphospholipid Antibody Carriers
Yu Zuo¹, Akrithi Udupa², Jennifer Fan¹, Una E. Makris¹, David Karp^1,3 and Yu-min Shen¹, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, ³Internal Medicine/Division of Rheumatic Diseases, University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Primary thrombosis prophylaxis among asymptomatic antiphospholipid antibody (aPL) carriers is challenging. The presence of aPL does not always lead to thromboembolic events. Additional factors…
Abstract Number: 1 • 2017 ACR/ARHP Annual Meeting
Anti-Phosphatidylserine/Prothrombin Antibodies (aPS/PT) As Potential Diagnostic Markers and Risk Predictors of Venous Thrombosis and Obstetric Complications in Antiphospholipid Syndrome
Hui Shi¹, Qiongyi Hu², Hui Zheng², Jialin Teng², Gary Norman³, Jinfeng Zhou⁴ and Chengde Yang², ¹Department of Rheumatology and Immunology, Ruijin Hospital,Shanghai Jiao Tong University School of Medicine, Shanghai, China, Shanghai, China, ²Ruijin Hospital,Shanghai Jiao Tong University School of Medicine, Shanghai, China, Shanghai, China, ³INOVA Diagnostics, Inc, San Diego, China, ⁴Werfen China, Shanghai, China
Background/Purpose: , Methods: , Results: and Conclusion: Background/Purpose:The antiphospholipid syndrome (APS) is a thrombophilic disorder characterized by clinical manifestations of vascular thrombosis and obstetric complications…
Abstract Number: 2 • 2017 ACR/ARHP Annual Meeting
Identifying “Second Hit” Risk Factor(s) Associated with Thrombosis and Pregnancy Morbidity in Ethnically Diverse Antiphospholipid Antibodies Positive Patients
Yu Zuo¹, Jennifer Fan², Ravi Sarode¹, Song Zhang², Una E. Makris¹, David Karp³ and Yu-min Shen², ¹University of Texas Southwestern Medical Center, Dallas, TX, ²University of Texas Southwestern Medical Center, dallas, TX, ³Rheumatology, UT Southwestern Med Ctr, Dallas, TX
Background/Purpose: The evaluation of thrombotic and pregnancy risks associated with antiphospholipid antibodies (aPL) in individual patients without APS clinical manifestation is challenging. Our aim is…
Abstract Number: 5 • 2017 ACR/ARHP Annual Meeting
Clinical Utility of the Global Antiphospholipid Syndrome Score (GAPSS) for Risk Stratification: A Pooled Analysisfrom 2273 Patients
Savino Sciascia¹, Massimo Radin², Giovanni Sanna³, Irene Cecchi⁴, Dario Roccatello⁵ and Maria Laura Bertolaccini⁶, ¹Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy, ²Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ³Louise Coote Lupus Unit, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom, London, United Kingdom, ⁴Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ⁵Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bo, Turin, Italy, ⁶Academic Department of Vascular Surgery, Cardiovascular Division, King's College London, United Kingdom, London, United Kingdom
Background/Purpose: Recently, our group conceived a risk score for clinical manifestations of APS [the global APS score or GAPSS] that takes into account the combination…
Abstract Number: 6 • 2017 ACR/ARHP Annual Meeting
Pregnancy Outcomes in a Cohort of Women with Antiphospholipid Syndrome. 25- Years Long-Term Observation
Dana Tegzova¹, Katerina Andelova², Iva Kucerova², Vera Vlasakova³, Stejskal Jan⁴, Putova Ivana⁵, Marta Olejarova⁶ and Ctibor Dostál⁷, ¹Clinical Department, Institute of Rheumatology and Rheumatological Clinic of 1st Medical Faculty, Charles University, Prague, Czech Republic, ²Institute of Mother and Child Care, Prague, Prague, Czech Republic, ³Dept.of Internal Medicine, City Hospital Ceske Budejovice, Ceske Budejovice, Czech Republic, ⁴1st Medical Faculty, Dpt. of Pathology, Charles University, Prague, Czech Republic, ⁵Institute of Rheumatology, Dpt. of Immunology, Prague, Czech Republic, ⁶Clinical, Institute of Rheumatology and Rheumatological Clinic of 1st Medical Faculty, Charles University, Prague, Czech Republic, ⁷Institute of Rheumatology and Rheumatological Clinic of 1st Medical Faculty, Charles University, Prague, Czech Republic
Background/Purpose: The goal of this long-term project was to investigate the course of pregnancy in patients with APS (primary or secondary with SLE) in 1993-2017,…
Abstract Number: 8 • 2017 ACR/ARHP Annual Meeting
Antiphospholipid Syndrome Leukocytes Demonstrate Increased Adhesive Potential: a Search for Novel Therapeutic Targets
Gautam Sule¹, William J. Kelley¹, Srilakshmi Yalavarthi¹, Alison Banka¹, Omolola Eniola-Adefeso¹ and Jason S. Knight², ¹University of Michigan, Ann Arbor, MI, ²., University of Michigan, Ann Arbor, MI
Background/Purpose: Adhesion of leukocytes to the endothelium is an initiating event in the thrombosis inherent to antiphospholipid syndrome (APS). Over the years, a number of…
Abstract Number: 13 • 2017 ACR/ARHP Annual Meeting
Epidemiology of Antiphospholipid Syndrome: A Population-Based Study
Ali Duarte-Garcia¹, Michael Pham¹, Cynthia S. Crowson², Kevin Moder³, Rajiv Pruthi⁴ and Eric L. Matteson⁵, ¹Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ³Rheumatology, Mayo Clinic, Rochester, MN, ⁴Mayo Clinic, R, MN, ⁵Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN
Background/Purpose: The epidemiology of definite antiphospholipid syndrome (APS) in the general population has not been described. A recent meta-analysis (Andreoli L, et al. Arth Care…
Abstract Number: 14 • 2017 ACR/ARHP Annual Meeting
Abnormalities in Th1, Th2 and Th17 Lymphoid Subpopulations in Long-Term Evolution Primary Antiphospholipid Syndrome
Gabriela Medina¹, Oscar I Florez-Durante², Laura Arcelia Montiel Cervantes³, Rubiraida Molina Aguilar², Elba Reyes Maldonado² and Luis J. Jara⁴, ¹Clinical Research Unit, Hospital de Especialidades Centro Medico La Raza,IMSS, Mexico City, Mexico, ²Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Mexico City, Mexico, ³Hematology Laboratory, Hospital de Especialidades Centro Médico La Raza, IMSS, Mexico City, Mexico, ⁴Direction of Education and Research, Hospital de Especialidades Centro Médico La Raza, IMSS, Mexico City, Mexico
Background/Purpose: Primary antiphospholipid antibody syndrome (PAPS) is characterized by recurrent thrombosis and pregnancy morbidity in the presence of antiphospholipid antibodies (aPL). Lymphoid subpopulations and innate…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].